ArticleBlood2013
A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- In Vitro Bone Marrow-Derived Dendritic Cells (BMDC) Generation for Antigen Presentation Assay.Bio-protocol · 2025Article
- OTU deubiquitinases in cancer pathogenesis and precision therapy.American journal of cancer research · 2025Review
- Rab8a restores diverse innate functions in CD11cNature communications · 2024Article
- miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.Cell death discovery · 2023Article
- Review
- YOD1 serves as a potential prognostic biomarker for pancreatic cancer.Cancer cell international · 2022Article
- Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARActa pharmaceutica Sinica. B · 2022Article
- M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway.Cell death discovery · 2021Article
- A Mouse Model of PPRV Infection for Elucidating Protective and Pathological Roles of Immune Cells.Frontiers in immunology · 2021Article
- Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity.Cell reports · 2020Article
- Key Modules and Hub Genes Identified by Coexpression Network Analysis for Revealing Novel Biomarkers for Spina Bifida.Frontiers in genetics · 2020Article
- IL-36α Promoted Wound Induced Hair Follicle Neogenesis via Hair Follicle Stem/Progenitor Cell Proliferation.Frontiers in cell and developmental biology · 2020Article
- Divergent Effects of a Transient Corticosteroid Therapy on Virus-Specific Quiescent and Effector CD8Frontiers in immunology · 2019Article
- Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.Nature communications · 2017Article
- Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.Journal of virology · 2014Article
- Protein quality control in the endoplasmic reticulum.F1000prime reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigen presenting cells (APCs) that express a catalytically inactive version of the deubiquitylase YOD1 (YOD1-C160S) present exogenous antigens more efficiently to CD8(+) T cells, both in vitro and in vivo. Compared with controls, immunization of YOD1-C160S mice led to greater expansion of specific CD8(+) T cells and showed improved control of infection with a recombinant -herpes virus, MHV-68, engineered to express SIINFEKL peptide, the ligand for the ovalbumin-specific TCR transgenic OT-I cells. Enhanced expansion of specific CD8(+) T cells was likewise observed on infection of YOD1-C160S mice with a recombinant influenza A virus expressing SIINFEKL. YOD1-C160S APCs retained antigen longer than did control APCs. Enhanced crosspresentation by YOD1-C160S APCs was transporter associated with antigen processing (TAP1)-independent but sensitive to inclusion of inhibitors of acidification and of the proteasome. The activity of deubiquitylating enzymes may thus help control antigenspecific CD8(+) T-cell responses during immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.